摘要
目的比较替格瑞洛与氯吡格雷治疗冠心病心肌缺血的临床疗效。方法将焦作煤业(集团)有限责任公司中央医院2017年6月—2018年7月期间诊治的84例冠心病心肌缺血患者进行研究,按随机抽签法将所有患者分为对照组42例和观察组42例。对照组患者接受氯吡格雷+拜阿司匹林治疗,观察组患者接受替格瑞洛+拜阿司匹林治疗。观察两组患者的临床效果及不良反应发生率。结果观察组患者的治疗总有效率(90.48%)明显高于对照组(73.81%);治疗后,观察组患者的心绞痛、心力衰竭、心肌梗死、消化道出血等不良反应发生率(9.52%)较低于对照组(26.19%)(P<0.05)。结论相比氯吡格雷,采用替格瑞洛治疗冠心病心肌缺血的效果比氯吡格雷更显著,且不良反应发生率较低,是安全有效的治疗方案,值得临床推广与应用。
Objective To compare the clinical effects of tigrilol and clopidogrel in the treatment of coronary heart disease(CHD) with myocardial ischemia. Methods 84 patients with coronary heart disease(CHD)with myocardial ischemia from June,2017 to Ju ly,2018 in the hospital were randomly divided into two groups:control group(n=42)and observation group(n=42). Patients in the control group were treated with clopidogrel aspirin,and those in the observation group were treated with tigrilobarbine aspirin. The clinical effects and the incidence of adverse reactions were observed in the two groups. Results The total effective rate of the patients in the observation group(90.48%)was significantly higher than that in the control group(73.8%). After treatment,the incidence of an gina pectoris, heart failure, myocardial infarction, gastrointestinal bleeding and other adverse reactions in the observation group (9.52%)was lower than those in the control group(26.19%)(P<0.05). Conclusion Compared with clopidogrel,tigrilol is more ef fective than clopidogrel in the treatment of coronary heart disease with myocardial ischemia,and the incidence of adverse reactions is lower. It is a safe and effective treatment scheme,which is worthy of clinical popularization and application.
作者
孙攀兴
SUN Pan-xing(Department of Cardiovascular Medicine,Jiaozuo Coal(Group) Co.,Ltd. Henan Central Hospital,Jiaozuo,Henan,454000,China)
出处
《黑龙江医学》
2019年第9期1098-1099,共2页
Heilongjiang Medical Journal
关键词
冠心病心肌缺血
替格瑞洛
氯吡格雷
临床疗效
不良反应
Coronary heart disease myocardial ischemia
Tigrilol
Clopidogrel
Clinical efficacy
Adverse reaction
